Overview

A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

Status:
RECRUITING

Trial end date:
2027-05-11

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of TAE+HAIC combined with camrelizumab and apatinib in the treatment of advanced liver cancer with high tumor load

Phase:

PHASE2

Details

Lead Sponsor:

Fujian Medical University

Treatments:

apatinib
camrelizumab